Tea Lanišnik-Rižner (Author), Trevor M. Penning (Author)

Abstract

Endometriosis is a common gynecological disorder, which is treated surgically and/ or pharmacologically with an unmet clinical need for new therapeutics. A completed phase I trial and a recent phase II trial that investigated the steroidal aldo-keto reductase 1C3 (AKR1C3) inhibitor BAY1128688 in endometriosis patients prompted this critical assessment on the role of AKR1C3 in endometriosis. This review includes an introduction to endometriosis with emphasis on the roles of prostaglandins and progesterone in its pathophysiology. This is followed by an overview of the major enzymatic activities and physiological functions of AKR1C3 and of the data published to date on the expression of AKR1C3 in endometriosis at the mRNA and protein levels. The review concludes with the rationale for using AKR1C3 inhibitors, a discussion of the effects of AKR1C3 inhibition on the pathophysiology of endometriosis and a brief overview of other drugs under clinical investigation for this indication.

Keywords

progesterone;androgens;endometriosis;

Data

Language: English
Year of publishing:
Typology: 1.02 - Review Article
Organization: UL MF - Faculty of Medicine
UDC: 618.1
COBISS: 34486233 Link will open in a new window
ISSN: 1096-1186
Views: 360
Downloads: 112
Average score: 0 (0 votes)
Metadata: JSON JSON-RDF JSON-LD TURTLE N-TRIPLES XML RDFA MICRODATA DC-XML DC-RDF RDF

Other data

Secondary language: Slovenian
Secondary keywords: progesteron;androgeni;endometrioza;
Type (COBISS): Article
Pages: str. 1-14
Issue: ǂVol. ǂ152
Chronology: Feb. 2020
DOI: 10.1016/j.phrs.2019.104446
ID: 13184878